表紙
市場調查報告書

青年性黃斑部病變(Stargardt disease):開發中產品分析

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 257806
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
青年性黃斑部病變(Stargardt disease):開發中產品分析 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 93 Pages
簡介

青年性黃斑部病變是兒童期·少年期發病的遺傳性眼科疾病,其最常見的形態被稱作為斯特格氏病(Stargardt disease)。斯特格氏病是先天性的平常染色體隱性遺傳症候群。主要的症狀·前兆有視野模糊,暗點呈現在視野中心部位上,無法從事讀書和精細的作業。主要的風險要素有動脈硬化症和高膽固醇症,抽煙,高血壓等。

本報告提供全球各國治療青年性黃斑部病變(Stargardt disease)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

青年性黃斑部病變概要

治療藥的開發

  • 青年性黃斑部病變開發中產品:概要
  • 企業所開發的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Acucela Inc.
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Copernicus Therapeutics Inc
  • Grupo Ferrer Internacional SA
  • Iris Pharma
  • Sanofi

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11557IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration - Pipeline Review, H2 2019, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape.

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Juvenile Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Juvenile Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Juvenile Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Juvenile Macular Degeneration (Stargardt Disease) - Overview
  • Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development
    • Acucela Inc
    • Alkeus Pharmaceuticals Inc
    • Alpine Biotherapeutics Corp
    • Astellas Pharma Inc
    • Beam Therapeutics Inc
    • Biogen Inc
    • Biophytis SA
    • Cardax Inc
    • Copernicus Therapeutics Inc
    • Generation Bio Corp
    • Grupo Ferrer Internacional SA
    • Ichor Therapeutics Inc
    • IVERIC bio Inc
    • Katairo GmbH
    • Lin Bioscience Inc
    • ProQR Therapeutics NV
    • Sanofi
    • Spark Therapeutics Inc
    • Stargazer Pharmaceuticals Inc
    • Vision Medicines Inc
    • WAVE Life Sciences Ltd
  • Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles
    • ALK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacincaptad pegol sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emixustat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FAB-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Leber's Congenital Amaurosis and Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBS-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSRABCA-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QR-1011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme for Age Related Macular Degeneration and Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-422459 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • soraprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STG-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects
  • Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 26, 2019: Biophytis announces it presented one oral and one poster presentation at the MaculART meeting in Paris, France
      • Jun 09, 2019: Acucela receives Orphan Designation From the EMA for Emixustat for the Treatment of Stargardt Disease
      • Apr 26, 2019: Belite Bio to trial new therapy for macular degeneration
      • Nov 12, 2018: Acucela enrols first patient in Phase III emixustat trial
      • Sep 18, 2018: FDA grants Lin BioScience Rare Pediatric Disease status for LBS-008 to treat Stargardt Disease
      • Jun 27, 2018: Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease
      • Oct 26, 2017: Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease
      • Sep 10, 2017: Acucela Receives New Patent Covering Method of Use for Emixustat Hydrochloride
      • Jul 26, 2017: Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases, Provides Update on Zimura
      • Jan 26, 2017: Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease
      • Jan 05, 2017: Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease
      • May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
      • Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
      • Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
      • Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt's Macular Degeneration Phase 1 Trial in the United Kingdom
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 5: Products under Development by Companies, H2 2019
  • Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 7: Products under Development by Universities/Institutes, H2 2019
  • Table 8: Number of Products by Stage and Target, H2 2019
  • Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 10: Number of Products by Stage and Route of Administration, H2 2019
  • Table 11: Number of Products by Stage and Molecule Type, H2 2019
  • Table 12: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Acucela Inc, H2 2019
  • Table 13: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals Inc, H2 2019
  • Table 14: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alpine Biotherapeutics Corp, H2 2019
  • Table 15: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc, H2 2019
  • Table 16: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Beam Therapeutics Inc, H2 2019
  • Table 17: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Biogen Inc, H2 2019
  • Table 18: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Biophytis SA, H2 2019
  • Table 19: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Cardax Inc, H2 2019
  • Table 20: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics Inc, H2 2019
  • Table 21: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Generation Bio Corp, H2 2019
  • Table 22: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Grupo Ferrer Internacional SA, H2 2019
  • Table 23: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Ichor Therapeutics Inc, H2 2019
  • Table 24: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by IVERIC bio Inc, H2 2019
  • Table 25: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Katairo GmbH, H2 2019
  • Table 26: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Lin Bioscience Inc, H2 2019
  • Table 27: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ProQR Therapeutics NV, H2 2019
  • Table 28: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Sanofi, H2 2019
  • Table 29: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Spark Therapeutics Inc, H2 2019
  • Table 30: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Stargazer Pharmaceuticals Inc, H2 2019
  • Table 31: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Vision Medicines Inc, H2 2019
  • Table 32: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by WAVE Life Sciences Ltd, H2 2019
  • Table 33: Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Targets, H2 2019
  • Figure 4: Number of Products by Stage and Targets, H2 2019
  • Figure 5: Number of Products by Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top